EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes

Masliyana Husin, Peter Seah Keng Tok, Jing Lian Suah, Boon Hwa Tng, Thevesh Thevananthan, Kalaiarasu M Peariasamy, Sheamini Sivasampu

The Journal of Infection in Developing Countries · 2025

DOI: 10.3855/jidc.18946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Masliyana Husin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia. Hauptthemen laut MEDLINE: COVID-19, Immunization, Secondary, SARS-CoV-2, Vaccine Efficacy. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Evidence of the waning immunity of coronavirus disease 2019 (COVID-19) primary vaccination, and immune evasion by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to the rollout of booster vaccination in many countries. Assessing the effectiveness of booster vaccination against severe COVID-19 outcomes is crucial during the transition to endemicity. Methodology: We conducted a population-based, matched case-control study in Malaysia to estimate the marginal vaccine effectiveness (mVE) of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against COVID-19 related intensive care unit (ICU) admission and death in Delta-predominant and Omicron-predominant periods.

Results

Receipt of a booster vaccination – either homologous or heterologous for CoronaVac, and homologous for BNT162b2 – demonstrated mVE estimates of at least 70% against ICU admission and at least 80% against death, compared to BNT162b2 primary vaccination, in both periods. Overall, the mVE estimates were 10–20 percentage points lower in the Omicron-predominant period than in the Delta-predominant period.

Conclusions

Our study reaffirms that the administration of booster vaccination increases protection against severe COVID-19 outcomes for BNT162b2 and CoronaVac primary vaccination recipients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Immunization, SecondarySARS-CoV-2Vaccine EfficacyCOVID-19 VaccinesHumansBNT162 VaccineMalaysiaMaleFemaleMiddle AgedCase-Control StudiesAdultAgedIntensive Care UnitsYoung AdultVaccines, Inactivated

Stichwörter der Autor:innen

BNT162b2COVID-19CoronaVacSARS-CoV-2boostervaccines

Substanzen

BNT162 VaccineCOVID-19 Vaccinessinovac COVID-19 vaccineVaccines, Inactivated

Autor:innen und Institutionen

  • Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.
  • Disease Control Division, Ministry of Health Malaysia, Putrajaya, Malaysia.

Zitieren

APA

Husin, M., Tok, P. S. K., Suah, J. L., Tng, B. H., Thevananthan, T., Peariasamy, K. M., & Sivasampu, S. (2025). Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.18946

Vancouver

Husin M, Tok PSK, Suah JL, Tng BH, Thevananthan T, Peariasamy KM, et al. Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.18946

BibTeX
@article{Husin2025,
  author = {Husin, Masliyana and Tok, Peter Seah Keng and Suah, Jing Lian and Tng, Boon Hwa and Thevananthan, Thevesh and Peariasamy, Kalaiarasu M and Sivasampu, Sheamini},
  title = {Effectiveness of homologous and heterologous BNT162b2 and CoronaVac booster vaccination against severe COVID-19 outcomes},
  journal = {The Journal of Infection in Developing Countries},
  year = {2025},
  doi = {10.3855/jidc.18946}
}
Kostenlos starten →